Oral Disease-Modifying Treatments for Multiple Sclerosis: The Story So Far

ISSN： 1172-7047

Source： CNS Drugs, Vol.21, Iss.6, 2007-01, pp. : 483-502

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

US FDA-Approved Disease-Modifying Treatments for Multiple Sclerosis: Review of Adverse Effect Profiles

By Steven L. Galetta Clyde Markowitz

CNS Drugs, Vol. 19, Iss. 3, 2005-01 ,pp. : 239-252

Adis International

Access to resources Recommend Favorite

Disease Modifying Treatments for Multiple Sclerosis: What is on the Horizon?

By Weilbach F.X. Gold R.

CNS Drugs, Vol. 11, Iss. 2, 1999-02 ,pp. : 133-157

Adis International

Access to resources Recommend Favorite

Disease-Modifying Agents for Multiple Sclerosis: Recent Advances and Future Prospects

By Menge Til

Drugs, Vol. 68, Iss. 17, 2008-01 ,pp. : 2445-2468

Adis International

Access to resources Recommend Favorite

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis: A Comprehensive Overview

By Johnston Jessica

Drugs, Vol. 72, Iss. 9, 2012-06 ,pp. : 1195-1211

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents

By Amato Maria Pia

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2115-2126

Informa Healthcare

Access to resources Recommend Favorite